Voxelotor
- Generic Name
- Voxelotor
- Brand Names
- Oxbryta
- Drug Type
- Small Molecule
- Chemical Formula
- C19H19N3O3
- CAS Number
- 1446321-46-5
- Unique Ingredient Identifier
- 3ZO554A4Q8
- Background
Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications arising from the blockage of blood vessels....
- Indication
In the US, voxelotor is indicated to treat sickle cell disease in both adult and pediatric patients aged 4 years and older. In Europe, it is indicated for the treatment of hemolytic anemia due to sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older as monotherapy or in combination with hydroxyurea.
- Associated Conditions
- Hemolytic Anemia, Sickle Cell Disease (SCD)
- Associated Therapies
- -
Assessing Physical Function in Sickle Cell Patients Taking Voxelotor
- First Posted Date
- 2023-09-05
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Inova Health Care Services
- Target Recruit Count
- 10
- Registration Number
- NCT06023199
- Locations
- 🇺🇸
Inova Schar Cancer Institute, Falls Church, Virginia, United States
Voxelotor CYP and Transporter Cocktail Interaction Study
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 44
- Registration Number
- NCT05981365
- Locations
- 🇺🇸
ICON Early Phase Services, LLC, San Antonio, Texas, United States
Voxelotor for Improving Oxygen Saturation in Adults
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Duke University
- Target Recruit Count
- 3
- Registration Number
- NCT05289570
- Locations
- 🇺🇸
Duke University Health System, Durham, North Carolina, United States
The Effect of Voxelotor on Cerebral Hemodynamic Response in Children with Sickle Cell Anemia
- First Posted Date
- 2021-08-24
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Amy Tang
- Target Recruit Count
- 22
- Registration Number
- NCT05018728
- Locations
- 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸Aflac Sickle Cell Comprehensive Clinics at Children's Healthcare of Atlanta, Scottish Rite, Atlanta, Georgia, United States
Expanded Access Protocol for Adults and Pediatric Patients With Sickle Cell Disease Who Have No Alternative Treatment Options
- Conditions
- First Posted Date
- 2021-01-26
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Pfizer
- Registration Number
- NCT04724421
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Rady Children's Hospital San Diego, San Diego, California, United States
🇺🇸Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States
Voxelotor Sickle Cell Exercise Study
- First Posted Date
- 2020-10-09
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Elizabeth Yang, MD, PhD
- Target Recruit Count
- 14
- Registration Number
- NCT04581356
- Locations
- 🇺🇸
Pediatric Specialist of Virginia, Fairfax, Virginia, United States
Actigraphy Improvement With Voxelotor (ActIVe) Study
- First Posted Date
- 2020-05-22
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 25
- Registration Number
- NCT04400487
- Locations
- 🇺🇸
The Children's Hospital at Montefiore, Bronx, New York, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 12
- Registration Number
- NCT04335721
- Locations
- 🇺🇸
University of Illinois, Chicago, Illinois, United States
Dose Escalation Study to Evaluate the Safety, Tolerability, PK and PD of Voxelotor in Patients With SCD
- First Posted Date
- 2020-01-30
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT04247594
- Locations
- 🇬🇧
Homerton University, London, United Kingdom
🇬🇧Royal London Hospital, Barts Health NHS Trust, London, United Kingdom
🇬🇧King's College Hospital, London, United Kingdom
Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease
- First Posted Date
- 2020-01-06
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 236
- Registration Number
- NCT04218084
- Locations
- 🇪🇬
Cairo University Hospital, Abu El Rish Hospital, Cairo, Egypt
🇪🇬Abu Elrish Children Hospital, Cairo, Egypt
🇪🇬Egyptian Thalassemia Association (satellite site), Cairo, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.